TFX
$109.00
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
Intraday
Recent News
3 Reasons TFX is Risky and 1 Stock to Buy Instead
Over the last six months, Teleflex’s shares have sunk to $113.26, producing a disappointing 13% loss - a stark contrast to the S&P 500’s 4.8% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
Teleflex Reshapes Portfolio With US$1b Plan For EPS And Balance Sheet
Teleflex (NYSE:TFX) plans to divest selected businesses and use about US$1b for share repurchases and debt reduction. The company expects these moves to sharpen its portfolio focus and support future earnings per share. Management is positioning the balance sheet for greater financial flexibility following the divestitures. Teleflex, a medical technology company, generates revenue from devices used in critical care and surgical settings. For investors, portfolio changes on this scale can...
Teleflex Q4 Earnings Call Highlights
Teleflex (NYSE:TFX) outlined a major portfolio transition and provided an updated financial framework as the company reported year-end 2025 results, emphasizing the planned divestitures of its Acute Care, Interventional Urology, and OEM businesses and the creation of a more focused “RemainCo.” Manag
TFX Q4 Earnings & Revenues Miss, Margins Down, Stock Up in After-Market
Teleflex Q4 earnings and revenues miss estimates as margins shrink, but shares rise 1.7% after hours amid 2026 growth guidance and portfolio reshuffle.